Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Discount Classification: Will Trump And Grassley Tag Team Against Pharma?

Executive Summary

Confirmation hearing for HHS Nominee Price could give Sen. Grassley chance to get new administration on record prioritizing enforcement against drugs that have been providing smaller than appropriate Medicaid discounts.

You may also be interested in...



Medicaid Drug Rebates Will Get Closer Scrutiny From CMS, Verma Pledges

CMS Administrator-nominee Seema Verma promises stronger agency oversight of Medicaid drug rebate program in response to question from Sen. Grassley during Senate confirmation hearing.

Part D Donut Hole Provisions May Not Be Best Way To Ensure Access, Price Says

HHS Secretary nominee suggests there may be better ways to close the Medicare Part D donut hole during his confirmation hearing before the Senate Finance Committee; physician payment transparency, vaccines and HHS price negotiation in Medicare also came up during the session.

Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates

$465m settlement with DOJ to resolve questions about EpiPen's classification is roughly the size of autoinjector's Medicaid and Medicare sales last year; Mylan expects to enter corporate integrity agreement.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel